• 2008

    First in the world to develop heart progenitor cells, giving new hope for testing drugs and treating heart failure patients. (Dr. Gordon Keller)

  • 2011

    Generated polyhormonal cells that were insulin producing. (Dr. Gordon Keller)

  • 2012

    Identify new approaches to mature liver cells to stage of efficient drug metabolization. (Dr. Gordon Keller)

  • November
    Isolate pure population of cardiomyocytes and identifies epicardium and endocardium. (Dr. Gordon Keller)

  • 2015

    Discover a pre-leukemic stem cell that may be the first step in initiating disease and also the culprit that evades therapy and triggers relapse in patients with acute myeloid leukemia (AML). (Dr. John Dick)

  • May
    Develop human cartilage tissue from human stem cells. (Dr. Gordon Keller)

  • August
    Demonstrate a new method to produce cholangiocytes (bile duct cells) from human pluripotent stem cells by providing the stem cells with certain activators at specific times during the production process. (Dr. Gordon Keller and Dr. Shinichiro Ogawa)

  • 2016

    December 12
    McEwen Centre for Regenerative Medicine receives backing from BlueRock Therapeutics. Work of UHN scientists among first projects for new stem-cell research company to commercialize an approach to regenerating heart muscle in patients who have had a heart attack or suffer from chronic heart failure.

  • December 14
    Develop the first functional pacemaker cells from human stem cells, paving the way for alternate, biological pacemaker therapy. (Dr. Gordon Keller and Dr. Stephanie Protze)

  • 2017

    August 24
    Develop a new method to identify and purify cells that develop into insulin-producing cells from human stem cells, creating opportunities for new therapies and safer transplants in patients with type 1 diabetes. (Dr. Maria Cristina Nostro)

  • 2018

    December 6
    McEwen Stem Cell Institute is established.

  • 2019

    August 8
    Bayer announces USD $1 billion acquisition of BlueRock Therapeutics, a company scientifically co-founded by Drs. Gordon Keller and Michael Laflamme.

  • November 6
    Dr. Gordon Keller receives top award — 2019 Ogawa-Yamanaka Stem Cell Prize—for his work in differentiating stem cells into multiple cell types.

  • 2020

    July 7
    Pioneer the generation of functional liver blood vessel cells from stem cells, enabling the development of new therapies for disorders such as hemophilia A. (Dr. Gordon Keller)

  • September 25
    Develop first optical map of electric activity from engrafted stem cell-derived heart cells provides key insights on electric function. (Dr. Michael Laflamme)

  • October 11
    Dr. Cristina Nostro receives Business Excellence Award for Innovation and Science from the Italian Chamber of Commerce Canada. new therapies for valve diseases.

  • October 27
    Identify key signalling molecule responsible for generating endocardial cells, which line the inside of the heart, paving the way for new therapies for valve diseases (Dr. Gordon Keller)

  • November 25
    Dr. Gordon Keller received Bloom Burton Award for his work as the scientific co-founder of BlueRock Therapeutics.

  • November 27
    Dr. Cristina Nostro receives 1 of 2 national CIHR-JDRF grants totalling $3M to develop stem cell-based therapies for Type 1 Diabetes. She leads an expert team of scientists across Canada with expertise in stem cell biology, vascular biology, islet transplantation and beta cell biology.

  • December 16
    Drs. Gordon Keller and Michael Laflamme receive UHN Local Impact Award for Commercialization in recognition of their pioneering work that led to the creation of BlueRock Therapeutics.

  • 2021

    May 26
    Dr. Gordon Keller develops a scalable protocol to develop heart muscle from human pluripotent stem cells. These cells have adult-like features, and can be used for disease modelling and treatment.

  • June 2
    Dr. Gordon Keller named co-recipient of 2021 Scientific Grand Prize from the Lefoulon Delalande Foundation at the Institute de France.

  • September 3
    Dr. Cristina Nostro and Dr. Sara Vasconcelos show that microvessels can increase the survival and functionality of transplanted pancreatic cells

  • November 15
    Dr. Shinichiro Ogawa uses pluripotent stem cells to generate cholangiocytes, which can be used to restore bile function in patients with biliary disease.

  • December 20
    Dr. Gordon Keller identifies pluripotent stem cell-derived blood cell precursor that gives rise to multiple blood lineages.

  • 2022

    January 28
    Dr. Michael Laflamme develops new technique to generate mature heart cells that confer improved outcomes in laboratory models of heart disease.

  • March 31
    Dr. Cristina Nostro develops new method to improve safety of cell therapy for Type 1 Diabetes to mark 100 years since insulin was first used in clinic.

  • April 5
    Dr. Gordon Keller demonstrates reversal of hemophilia A with proof-of-concept cell therapy in laboratory model.

Back to Top